ChromaDex Corp (CDXC, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. ChromaDex Corp is a natural products company. The company discovers, acquires, develops and commercializes patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skincare and pharmaceutical markets. ChromaDex Corp has a market cap of $254.110 million; its shares were traded at around $4.72 with and P/S ratio of 7.54. ChromaDex Corp had annual average EBITDA growth of 33.80% over the past five years.
For the last quarter ChromaDex Corp reported a revenue of $7.53 million, compared with the revenue of $9.60 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $21.2 million, a decrease of 20.9% from the previous year. For the last five years ChromaDex Corp had an average revenue growth rate of 19.7% a year.
The reported loss per diluted share was 26 cents for the year, compared with the loss per share of $0.15 in the previous year. The ChromaDex Corp had an operating margin of -77.25%, compared with the operating margin of -8.37% a year before. The 10-year historical median operating margin of ChromaDex Corp is -34.16%. The profitability rank of the company is 4 (out of 10).
At the current stock price of $4.72, ChromaDex Corp is traded at 13.7% premium to its historical median P/S valuation band of $4.15. The P/S ratio of the stock is 7.54, while the historical median P/S ratio is 6.65. The stock gained 70.57% during the past 12 months.
For the complete 20-year historical financial data of CDXC, click here.
